ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

• Published in: NPJ precision oncology Vol. 9; no. 1; pp. 86 - 23
• Main Authors: Herzog, Thomas J., Krivak, Thomas C., Bush, Stephen, Diaz, John P., Lentz, Scott, Nair, Navya, Zgheib, Nadim Bou, Gunderson-Jackson, Camille, Barve, Abhijit, Denning, Krista L., Lirette, Seth T., Howard, Candace M., Valluri, Jagan, Claudio, Pier Paolo
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 25.03.2025; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67/1517/1709; 692/308/575; 692/4028/67/1517/1709; Cancer Research; Chemotherapy; Clinical outcomes; Clinical trials; Gene Therapy; Human Genetics; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Ovarian cancer; Response rates
• ISSN: 2397-768X; 2397-768X
• DOI: 10.1038/s41698-025-00874-0

Patients with recurrent platinum-resistant ovarian cancer ( PROC ) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells ( CSCs ). The NCT03949283 randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or the best physician-choice regimen selected from the same list of thirteen mono or combination chemotherapies. The primary outcome was objective response rate ( ORR ) assessed on CT scans using the RECIST 1.1 criteria at 6 months follow-up. Subjects treated with the ChemoID assay had an ORR of 55% (CI 95 39% - 73%), compared to 5% (CI 95 0% - 11%) for those treated with physician’s choice chemotherapy ( p  <0.0001). Secondary endpoints of duration of response ( DOR ) and progression-free survival ( PFS ) of subjects treated with chemotherapies guided by the ChemoID assay versus physician’s choice chemotherapy were a median of 8 months vs. 5.5 months ( p  <0.0001), and 11.0 months (CI 95 8.0– NA) vs 3.0 months (CI 95 2.0– 3.5) with 27% of hazard ratio (CI95, 0.15–0.49; p  <0.001), respectively.